Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
517 stopped studies mapped to Malignant Liver Neoplasm and descendants · 92% state a reason
Over the 517 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06848556 | Evaluate the Effect of Tirazamine on Primary Liver Cancer. | Phase 1 / Phase 2 | terminated | Feb 27, 2025 | Zhejiang Raygene Pharmaceuticals Co., Ltd | Company Operational Strategy Adjustment | Sponsor / business decision |
| NCT04268888 | Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC(TACE-3) | Phase 2 / Phase 3 | suspended | Feb 13, 2020 | The Clatterbridge Cancer Centre NHS Foundation Trust | Analysis meant the study should close to recruitment | Enrollment / accrual |
| NCT04709380 | Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced… | Phase 3 | terminated | Jan 14, 2021 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | IDMC recommended to terminate the study since Interim analysis showed that the experimental group… | Efficacy / futility |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid… | Phase 1 | terminated | Jun 18, 2023 | Incyte Corporation | This was a strategic business decision. There were no safety concerns contributing to this decision. | Safety / toxicity |
| NCT01205828 | ABT-888 and Temozolomide for Liver Cancer | Phase 2 | terminated | Sep 21, 2010 | Georgetown University | Lack of efficacy | Efficacy / futility |
| NCT02935478 | Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver… | N/A | suspended | Oct 17, 2016 | St. Louis University | IRB reviewing study conduct and adverse events | Safety / toxicity |
| NCT02853500 | Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy… | Phase 4 | withdrawn | Aug 3, 2016 | Dana-Farber Cancer Institute | No participants enrolled. Inability to perform intraprocedural MRI with the intraarterial infusion… | Enrollment / accrual |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and…(MYCHELANGELO I) | Phase 1 / Phase 2 | terminated | Aug 11, 2022 | Omega Therapeutics | Sponsor decision to terminate after monotherapy dose escalation. | Sponsor / business decision |
| NCT05845502 | Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced… | N/A | terminated | May 6, 2023 | Shantou University Medical College | Failed to recruit more volunteers | Enrollment / accrual |
| NCT05776875 | Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | Phase 2 | terminated | Mar 20, 2023 | Yale University | Low enrollment | Enrollment / accrual |
| NCT04066660 | Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC) | N/A | terminated | Aug 26, 2019 | Hi-Q Marine Biotech International, Ltd. | After interim analysis, we planned to recruit 100 participants. However, due to COVID-19… | COVID-19 / pandemic |
| NCT05653427 | A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced… | Phase 2 | terminated | Dec 16, 2022 | Janssen Research & Development, LLC | N\~15 subjects data analysis did not meet statistical consideration of ORR and study… | Efficacy / futility |
| NCT05717400 | Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma… | Phase 4 | terminated | Feb 8, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT02878473 | Liver Transplantation for Early Intrahepatic Cholangiocarcinoma(LT for iCCA) | Phase 2 | terminated | Aug 25, 2016 | University Health Network, Toronto | Low accrual | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT05418387 | A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer… | N/A | withdrawn | Jun 14, 2022 | University of Arizona | The study will be withdrawn as the Principal Investigator, Ken Batai, left the institution prior to… | Investigator |
| NCT03145558 | TATE Versus TACE in Intermediate Stage HCC(TATE) | Phase 2 | terminated | May 9, 2017 | Teclison Ltd. | Landscape changed and the study population is no longer suitable for the study treatment. | Other (stated, no rule matched) |
| NCT01101906 | A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients… | Phase 2 | terminated | Apr 12, 2010 | Astellas Pharma Inc | Company decided not to pursue the development of this drug in this patient population at this time | Sponsor / business decision |
| NCT02512692 | Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma | N/A | terminated | Jul 31, 2015 | Medical University of South Carolina | Enrollment closed by internal scientific review committee due to slow accrual. | Enrollment / accrual |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT00667628 | Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE)… | Phase 2 | terminated | Apr 28, 2008 | Taiho Oncology, Inc. | Terminated due to safety concerns. | Safety / toxicity |
| NCT00687596 | Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular… | Phase 2 | terminated | Jun 2, 2008 | Taiho Oncology, Inc. | Terminated due to safety concerns | Safety / toxicity |
| NCT00756782 | A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With… | Phase 2 | withdrawn | Sep 22, 2008 | Taiho Oncology, Inc. | Terminated due to safety concerns. | Safety / toxicity |
| NCT03960008 | Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as…(SBRTvsTACE) | Phase 3 | terminated | May 22, 2019 | Lahey Clinic | This study was closed early due to lack of enrollments and insufficient funding. | Enrollment / accrual |
| NCT06006286 | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally… | Phase 1 / Phase 2 | withdrawn | Aug 23, 2023 | M.D. Anderson Cancer Center | 0 participants registered | Other (stated, no rule matched) |
| NCT05352542 | GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma | Phase 1 | terminated | Apr 29, 2022 | jianming xu | achieve the proof of concept | Other (stated, no rule matched) |
| NCT06337162 | Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)(HCC) | Phase 1 | withdrawn | Mar 29, 2024 | Abramson Cancer Center at Penn Medicine | Incyte made a strategic business decision to stop enrollment to all ongoing oral PD-L1 (99280)… | Enrollment / accrual |
| NCT04497038 | Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B… | Phase 1 / Phase 2 | terminated | Aug 4, 2020 | University of Michigan Rogel Cancer Center | loss of funding | Funding |
| NCT04931420 | Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive… | Phase 2 | withdrawn | Jun 18, 2021 | University of Chicago | PI left site | Investigator |
| NCT04212221 | MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in… | Phase 1 / Phase 2 | terminated | Dec 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | Due to the rapid shifting of liver cancer disease landscape and the company's adjustment of… | Sponsor / business decision |
| NCT02314052 | Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular… | Phase 1 / Phase 2 | terminated | Dec 10, 2014 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Sponsor decision | Sponsor / business decision |
| NCT02649868 | LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of… | N/A | terminated | Jan 8, 2016 | National Institutes of Health Clinical Center (CC) | unavailability of study device | Other (stated, no rule matched) |
| NCT05009953 | Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer | Phase 2 | terminated | Aug 18, 2021 | CSPC Ouyi Pharmaceutical Co., Ltd. | Internal strategy change. Not related to safety concerns. | Safety / toxicity |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | N/A | withdrawn | Jul 22, 2022 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04315883 | Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors | — | terminated | Mar 20, 2020 | Nemours Children's Clinic | PI left organization and discontinued study | Investigator |
| NCT04541173 | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable… | Phase 2 | terminated | Sep 9, 2020 | Aiwu Ruth He, MD | Due to slow accrual. | Enrollment / accrual |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT03958669 | Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCC(e:Med-HCC-2) | — | terminated | May 22, 2019 | University Hospital Tuebingen | Slow recruitment due to COVID-19 pandemic and several newly approved treatment options | COVID-19 / pandemic |
| NCT02762266 | Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or… | Phase 3 | terminated | May 4, 2016 | Stanford University | Business decision - funding | Funding |
| NCT05292443 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated… | — | withdrawn | Mar 23, 2022 | Geneplus-Beijing Co. Ltd. | No participants were enrolled | Enrollment / accrual |
| NCT03812562 | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical… | Early Phase 1 | terminated | Jan 23, 2019 | Northwestern University | Lack of funding | Funding |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT02722616 | Ultrasound Monitoring of Abdominal Soft Tissue | N/A | terminated | Mar 30, 2016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Ultrasound vendor cannot support the study | Other (stated, no rule matched) |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT04589884 | Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis &…(iEXMachyna3) | — | terminated | Oct 19, 2020 | IHU Strasbourg | Data acquisition not possible anymore | Other (stated, no rule matched) |
| NCT03753789 | Ablation Confirmation Study | N/A | terminated | Nov 27, 2018 | Ethicon, Inc. | Combined study endpoints with ongoing registry (NOLA/NEU\_2017\_04) | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT05514912 | Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without… | Phase 2 | withdrawn | Aug 25, 2022 | Emory University | PI has decided to terminate this study due to study supporter pulling support on this study. | Other (stated, no rule matched) |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | May 6, 2022 | Fusion Pharmaceuticals Inc. | Fusion announced that it is discontinuing this study as part of a portfolio prioritization and… | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 27, 2025source: clinicaltrials